In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Akero Therapeutics (AKRO), with a price target of $68.00. The company’s shares closed last Thursday at $27.73.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 13.5% and a 37.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Akero Therapeutics is a Strong Buy with an average price target of $60.17, an 118.7% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $82.00 price target.
See today’s analyst top recommended stocks >>
Based on Akero Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $29.71 million. In comparison, last year the company had a GAAP net loss of $15.61 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.